Quarterly Report • May 4, 2006
Quarterly Report
Open in ViewerOpens in native device viewer

Interim Report January – March 2006

Beiersdorf – Passion for Skin and Beauty Care


*excluding income from the sale of BSN medical

Beiersdorf – Passion for Skin and Beauty Care
In addition to Western Europe we concentrate on the growth markets China, Russia, Brazil, and India. In the fi rst quarter we were able to grow signifi cantly above-average in these strategic markets.

| Beiersdorf at a Glance | Jan. 1 – Mar. 31 | Jan. 1 – Mar. 31 |
|---|---|---|
| in € million (unless otherwise stated) | 2005 | 2006 |
| Sales | 1,173 | 1,275 |
| Change in % (nominal) | -0.1 | 8.7 |
| Change in % (adjusted for currency translation effects) | 0.4 | 6.2 |
| Consumer | 995 | 1,075 |
| tesa | 178 | 200 |
| EBITDA | 182 | 193 |
| Operating result (EBIT) | 145 | 162 |
| Profi t after tax | 92 | 462 |
| Profi t after tax (excluding special factors) | 92 | 101* |
| Return on sales (after tax) in % | 7.8 | 7.9* |
| Earnings per share in € | 1.20 | 1.32* |
| Gross cash fl ow | 158 | 140 |
| Capital expenditure (incl. fi nancial assets) | 28 | 24 |
| Research and development expenses | 24 | 27 |
| Employees (as of Mar. 31) | 16,721 | 17,059 |
*excluding income from the sale of BSN medical
** excluding income from the sale of BSN medical and expenses for the realignment
of the Consumer Supply Chain
| Sales | ||||||
|---|---|---|---|---|---|---|
| (in € million) | Jan. 1 – Mar. 31, | 2005 % of total |
Jan. 1 – Mar. 31, 2006 % of total |
nominal | Change in % adj. for curr. trans. effects |
|
| Consumer | 995 | 84.8 | 1,075 | 84.3 | 8.0 | 5.5 |
| tesa | 178 | 15.2 | 200 | 15.7 | 12.6 | 10.1 |
| 1,173 | 100.0 | 1,275 | 100.0 | 8.7 | 6.2 | |
| Operating result before depreciation and amortization (EBITDA) (in € million) |
% of sales | % of sales | Change in % nominal |
|||
| Consumer | 160 | 16.1 | 167 | 15.6 | 4.5 | |
| tesa | 22 | 12.3 | 26 | 12.9 | 18.2 | |
| 182 | 15.5 | 193 | 15.2 | 6.2 | ||
| Operating result (EBIT) | Change in % | |||||
| (in € million) | % of sales | % of sales | nominal | |||
| Consumer | 129 | 12.9 | 143 | 13.3 | 10.9 | |
| tesa | 16 | 8.8 | 19 | 9.6 | 22.7 | |
| 145 | 12.3 | 162 | 12.7 | 12.2 | ||
| Gross cash flow | Change in % | |||||
| (in € million) | % of sales | % of sales | nominal |
| Consumer | 140 | 14.1 | 125 | 11.6 | -10.9 |
|---|---|---|---|---|---|
| tesa | 18 | 10.2 | 15 | 7.7 | -14.8 |
| 158 | 13.5 | 140 | 11.0 | -11.3 |
| Sales | ||||||
|---|---|---|---|---|---|---|
| (in € million) | Jan. 1 – Mar. 31, | 2005 % of total |
Jan. 1 – Mar. 31, | 2006 % of total |
nominal | Change in % adj. for curr. trans. effects |
| Europe | 882 | 75.1 | 935 | 73.3 | 6.0 | 5.6 |
| Americas | 155 | 13.2 | 182 | 14.3 | 18.1 | 5.7 |
| Africa/Asia/Australia | 136 | 11.7 | 158 | 12.4 | 15.4 | 10.3 |
| 1,173 | 100.0 | 1,275 | 100.0 | 8.7 | 6.2 |
| Operating result (EBIT) | |||||
|---|---|---|---|---|---|
| (in € million) | % of sales | % of sales | Change in % nominal |
||
| Europe | 126 | 14.2 | 144 | 15.4 | 15.3 |
| Americas | 5 | 3.2 | 5 | 2.7 | -2.6 |
| Africa/Asia/Australia | 14 | 10.4 | 13 | 8.1 | -10.4 |
| 145 | 12.3 | 162 | 12.7 | 12.2 |
Figures in percent are calculated based on thousands of euros.

This selection of news from the first quarter shows the consistent implementation of our "Passion for Success" Consumer Business Strategy, which is enabling us to continually grow our global market share.
The JUVENA/La Prairie Group has a new name as of 2006: the "la prairie group" now unites la prairie, JUVENA, and MARLIES MÖLLER Beauty Hair Care brands,
Just two years after its launch, NIVEA FOR MEN has taken the number 1 position (according to ACNielsen) in China in February in the men's facial care segment. This market segment continues to offer substantial growth potential in China.
In February 2006, the fi rst steps in rea-

skin care offers major opportunities: the anti-aging
treatment with the skin's own creatine has been proven to help reduce the loss of skin elasticity, wrinkles, and dryness.
and SBT Skin Biology Therapy, which are positioned on the global cosmetics market.
In January 2006, the new NIVEA brand strategy was presented to trade partners in Russia. The focus on specifi c strong product categories was received very well, as were the latest product innovations.

ligning the Consumer Supply Chain were announced. In addition to shifting production of wound care products from Hamburg to Argentona (Spain), the possible closure
of the production facilities in Kungsbacka (Sweden) and Almere (The Netherlands) was also announced, along with the possible closure of the warehouses in The Netherlands and Belgium. The cost savings will

Beauty offers more than just reliable deodorant protection thanks to its 24-
hour formula. For the fi rst time, this product introduces the idea of beauty care into the deodorant product category. The product's recipe for success includes precious pearl ex tracts that eliminate unevenness and leave underarms feeling smooth and beautiful.

Eucerin Sensitive Skin started the new year with an international relaunch. Eucerin Sensitive Skin, which features Eucerin
pH5 Enzyme Protection, is a skin care line that has been proven to replenish the skin's own enzymes and activate the skin's natural defenses.
be leveraged for investments in brands and markets.
The Center for Applied Nanotechnology (CAN) was founded in Hamburg with Beiersdorf as a partner. CAN offers opportunities for developing new product technologies. Nanotechnology is already being used by Beiersdorf in many products, such as deodorants.

In the skin care prod uct category, NIVEA is considered the most
trusted brand in Europe. This designation was awarded for the sixth consecutive time by this year's "Reader's Digest Most Trusted Brands" survey. Readers in 14 European countries rewarded Beiersdorf for the high quality of the NIVEA brand, as well as for its consumer focus.

Please visit www.Beiersdorf.com for our Consumer Business Strategy along with full background information and additional current news.

In the fi rst quarter, the Group achieved sales growth of 6.2 % (adjusted for currency translation effects). The Consumer business segment contributed to this excellent result with sales up 5.5 %, while tesa sales increased by 10.1 %. At current exchange rates, sales increased by 8.7 % to €1,275 million in the fi rst quarter (previous year: €1,173 million).
| Income Statement | |||
|---|---|---|---|
| (in € million) | Jan. 1 – Mar. 31, 2005 |
Jan. 1 – Mar. 31, 2006 |
Change in % |
| Sales | 1,173 | 1,275 | 8.7 |
| Cost of goods sold | -393 | -421 | 7.1 |
| Gross profi t | 780 | 854 | 9.5 |
| Marketing and selling expenses | -542 | -590 | 8.8 |
| Research and development expenses | -24 | -27 | 9.5 |
| General and administrative expenses | -56 | -61 | 9.3 |
| Other operating result | -13 | -14 | 11.6 |
| Operating result (EBIT) | 145 | 162 | 12.2 |
| Income from the sale of BSN medical | - | 371 | - |
| Other fi nancial result | 2 | - | - |
| Profi t before tax | 147 | 533 | 263.4 |
| Taxes on income | -55 | -71 | 29.5 |
| Profi t after tax | 92 | 462 | 402.1 |
| Basic/diluted earnings per share (in €) | 1.20 | 6.09 | 409.2 |
The Group's operating result (EBIT) grew faster than sales, climbing to €162 million (previous year: €145 million). The EBIT margin rose to 12.7 % (previous year: 12.3 %). These fi gures do not yet include any restructuring expenses for the realignment of the Consumer Supply Chain, as the fi rst measures announced in February will not be implemented in concrete projects until later in 2006. The corresponding restructuring expenses will be reported for the fi rst time in the half-year report.
Income of €371 million (after tax: €361 million) was generated by the sale of Beiersdorf's share in BSN medical in February 2006.
Profi t after tax increased to €462 million (previous year: €92 million). The return on sales after tax rose to 36.2 % (previous year: 7.8 %). After adjustment for the sale of BSN medical, profi t after tax was €101 million and the return on sales was 7.9 %.
Beiersdorf's earnings per share based on 75,606,328 shares, rose to €6.09 (previous year: €1.20). The basic and diluted earnings per share were the same. After adjustment for the sale of BSN medical, earnings per share still rose to €1.32.

| Consumer | ||||
|---|---|---|---|---|
| (Jan. – March) | Europe | Americas | Africa/ Asia/ |
Total |
| (in € million) | Australia | |||
| Sales 2006 | 786 | 159 | 130 | 1,075 |
| Change (adjusted for | ||||
| currency translation effects) | 4.9 % | 4.9 % | 10.2 % | 5.5 % |
| Change (nominal) | 5.3 % | 17.0 % | 14.8 % | 8.0 % |
| EBIT 2006 | 129 | 4 | 10 | 143 |
| EBIT margin 2006 | 16.4 % | 2.5 % | 7.8 % | 13.3 % |
| EBIT 2005 | 112 | 5 | 12 | 129 |
| EBIT margin 2005 | 15.0 % | 3.6 % | 10.4 % | 12.9 % |
Sales rose by 5.5 %, adjusted for currency translation effects. At current exchange rates, the Consumer business segment achieved sales growth of 8.0 % to €1,075 million (previous year: €995 million). Strong double-digit growth was seen in particular in our focus regions of Eastern Europe, Latin America, and Asia.
NIVEA sales rose by 7.1 %. This positive development was driven primarily by NIVEA BEAUTÉ, NIVEA Hair Care Styling, and NIVEA FOR MEN. Eucerin and la prairie also generated above-average growth rates.
The Consumer business segment's operating result (EBIT) increased strongly to €143 million (previous year: €129 million). This EBIT growth was generated exclusively in Europe. The EBIT margin rose to 13.3 % (previous year: 12.9 %).
| Consumer Sales in Europe | |||||
|---|---|---|---|---|---|
| (Jan. – March) | Germany | Western Europe (excluding |
Eastern Europe | Total | |
| (in € million) | Germany) | ||||
| Sales 2006 | 243 | 439 | 104 | 786 | |
| Change (adjusted for | |||||
| currency translation effects) | 0.5 % | 4.2 % | 21.0 % | 4.9 % | |
| Change (nominal) | 0.5 % | 4.0 % | 26.1 % | 5.3 % |
In Europe, sales in the Consumer business segment increased by 4.9 % adjusted for currency translation effects. At current exchange rates, sales increased 5.3 % to €786 million (previous year: €746 million).
Sales to customers in Germany remained only at the previous year's level due mostly to a delay in the shipment of NIVEA SUN compared to the previous year. NIVEA FOR MEN and NIVEA BEAUTÉ performed well. Our Eucerin brand achieved excellent growth in the pharmacy business. Exports from Germany increased by 4.0 %.
In Western Europe, sales growth picked up again at +4.2 % (adjusted for currency trans lation effects). We saw particularly high growth in Switzerland, The Netherlands, and the Nordic countries. Sales growth in our other major markets, such as France and Italy, was also solid again.
In Eastern Europe, many of our affi liates started the new year with double-digit growth rates. Especially the excellent growth in the large markets of Poland and Russia contributed to the growth of the region, which totaled 21.0 % (adjusted for currency translation effects). In Russia, NIVEA FOR MEN and NIVEA deodorant performed particularly well. In Poland we were very successful with NIVEA deodorant and NIVEA VISAGE, as well as with the launch of NIVEA Hair Care Styling products.
The Consumer business segment in Europe recorded above-average EBIT growth, from €112 million in the previous year to €129 million. The EBIT margin rose to 16.4 % (previous year: 15.0 %).
| Consumer Sales in the Americas (Jan. – March) |
||||
|---|---|---|---|---|
| (in € million) | North America | Latin America | Total | |
| Sales 2006 | 91 | 68 | 159 | |
| Change (adjusted for currency translation effects) | -4.9 % | 22.0 % | 4.9 % | |
| Change (nominal) | 4.1 % | 40.0 % | 17.0 % |
In the Americas region, sales increased by 4.9 % (adjusted for currency translation effects). At current exchange rates, sales amounted to €159 million, up 17.0 % on the previous year (€136 million).
In North America, NIVEA FOR MEN performed well and growth was excellent in Canada. Streamlining of the product range in the United States in connection with the focus on our strong brands and later launch activities in comparison to the previous year offset this development. Sales were 4.9 % lower than previous year (adjusted for currency translation effects).
In Latin America, sales rose by 22.0 % (adjusted for currency translation effects), due to double-digit growth in nearly all countries in this core region.
EBIT for the Consumer business segment in this region amounted to €4 million (previous year: €5 million). The EBIT margin amounted to 2.5 % (previous year: 3.6 %).
| Consumer Sales in Africa/Asia/Australia |
|
|---|---|
| (Jan. – March) (in € million) |
Africa/Asia/ Australia |
| Sales 2006 | 130 |
| Change (adjusted for currency translation effects) | 10.2 % |
| Change (nominal) | 14.8 % |
At +10.2 %, Africa/Asia/Australia again achieved double-digit sales growth (adjusted for currency translation effects). With sales growth of over 40 %, which is particularly attributable to the success of NIVEA FOR MEN and NIVEA VISAGE, China far outperformed the rest of the market. Whitening products contributed in particular to the success of

NIVEA VISAGE. Australia, Korea, and South Africa also saw double-digit growth. In Japan, however, sales remained at the previous year's level. The reasons were that retailers had built up inventory last year for the successful launch of NIVEA body.
At current exchange rates, sales amounted to €130 million, up 14.8 % on the previous year (€113 million). EBIT for the Consumer business segment in this region amounted to €10 million (previous year: €12 million). The EBIT margin amounted to 7.8 % (previous year: 10.4 %).
| tesa (Jan. – March) |
Europe | Americas | Africa/ Asia/ |
Total |
|---|---|---|---|---|
| (in € million) | Australia | |||
| Sales 2006 | 149 | 23 | 28 | 200 |
| Change (adjusted for currency translation efffects) |
9.7 % | 12.1 % | 10.8 % | 10.1 % |
| Change (nominal) | 9.8 % | 26.4 % | 18.1 % | 12.6 % |
| EBIT 2006 | 15 | 1 | 3 | 19 |
| EBIT margin 2006 | 10.6 % | 3.4 % | 9.8 % | 9.6 % |
| EBIT 2005 | 14 | - | 2 | 16 |
| EBIT margin 2005 | 9.7 % | 0.2 % | 10.8 % | 8.8 % |
Adjusted for currency translation effects, tesa sales were up signifi cantly on the previous year at +10.1 %. This excellent result is partially due to the lower sales in the prior-year period compared to the good level for the year as a whole. At current exchange rates, tesa's sales amounted to €200 million, up 12.6 % on the previous year.
The strong growth in this segment was driven by both the industrial and the consumer businesses. In the industrial segment, the highlight was the positive growth in the automotive and automotive supply sector. tesa generated double-digit growth in the automotive segment as well as the printing and paper industry and electrical/electronics industry segments.
In the consumer business, the "do-it-yourself" segment saw strong double-digit growth, particularly thanks to the growth in the tesa Moll product group. The long, cold winter in Europe was a positive factor in this sales growth.
All regions contributed to this solid development. Particularly notable was the growth in North America (+18 % adjusted for currency translation effects) and in Eastern Europe (+21 % adjusted for currency translation effects).
EBIT climbed to €19 million (previous year: €16 million), while the EBIT margin rose to 9.6 % (previous year: 8.8 %).
| Balance Sheet | |||
|---|---|---|---|
| Assets (in € million) | Dec. 31, 2005 | Mar. 31, 2005 | Mar. 31, 2006 |
| Non-current assets | 962 | 1,055 | 947 |
| Inventories | 536 | 590 | 585 |
| Other current assets | 926 | 957 | 922 |
| Cash and cash equivalents | 483 | 255 | 980 |
| 2,907 | 2,857 | 3,434 | |
| Equity and liabilities (in € million) | Dec. 31, 2005 | Mar. 31, 2005 | Mar. 31, 2006 |
| Equity* | 1,293 | 1,133 | 1,734 |
| Non-current liabilies | 601 | 641 | 591 |
| Current liabilities | 1,013 | 1,083 | 1,109 |
* before appropriation of net retained profi ts
Inventories rose to €585 million since the beginning of the year, but were still under the level of the previous year. Within other current assets, the seasonal increase in trade receivables was offset by the sale of our investment in BSN medical (€77 million). Cash and cash equivalents increased signifi cantly due to the sale of BSN medical. Non-current liabilities changed only insubstantially as against the year-end. The rise in current liabilities is attributable to the higher pro visions for marketing and selling expenses, and for taxes on income.
| Financing Structure | |||
|---|---|---|---|
| Dec. 31, 2005 | 38 %44 % | 21 % | 35 % |
| Mar. 31, 2005 | 40 % | 22 % | 38 % |
| Mar. 31, 2006 | 51 % | 17 % | 32 % |
Equity Non-current liabilities Current liabilities

| Cash Flow Statement (in € million) |
Jan. 1 – Mar. 31, 2005 |
Jan. 1 – Mar. 31, 2006 |
|---|---|---|
| Cash and cash equivalents as of Jan. 1 | 290 | 483 |
| Gross cash fl ow | 158 | 140 |
| Change in working capital | -133 | -31 |
| Net cash fl ow from operating activities | 25 | 109 |
| Net cash fl ow from investing activities | -12 | 418 |
| Free cash fl ow | 13 | 527 |
| Net cash fl ow from fi nancing activities | -55 | -28 |
| Other changes | 7 | -2 |
| Net change in cash and cash equivalents | -35 | 497 |
| Cash and cash equivalents as of Mar. 31 | 255 | 980 |
Gross cash fl ow amounted to €140 million. Working capital increased by €31 million, €102 million less than in the previous year. Net cash fl ow from operating activities reached €109 million, €84 million more than in the previous year. We achieved a net cash fl ow from investing activities of €418 million, including a cash infl ow from the sale of our investment in BSN medical of €433 million. Free cash fl ow reached €527 million (€94 million excluding the net cash infl ow from the sale of BSN medical). Net cash outfl ow from fi nancing activities amounted to €28 million. Cash and cash equivalents rose to €980 million.
Beiersdorf invested €22 million (previous year: €27 million) in property, plant, and equipment and intangible assets. €18 million of this was attributable to the Consumer business segment (previous year: €20 million) and €4 million to tesa (previous year: €7 million).
The number of employees grew by 290 to 17,059 compared to the fi gure on December 31, 2005. As of March 31, 2006 13,423 employees worked in the Consumer business segment and 3,636 at tesa.
Employees by region as of March 31, 2006

The fi gures disclosed in this Interim Report were prepared in accordance with International Financial Reporting Standards (IFRS). The same accounting policies were used in the Interim Report as in the Annual Financial Statements for 2005.
The Interim Report was not reviewed by an auditor.
The declaration of compliance issued by the Supervisory Board and the Executive Board for fi scal 2005 regarding the recommendations of the German Corporate Governance Code in accordance with §161 of the Aktiengesetz (German Stock Corporation Act) was published at the end of December 2005 and is permanently available on our website at www.Beiersdorf.com.
We do not anticipate any major changes in the macroeconomic situation in 2006 over the previous year. Our assessment continues to be based on current growth rates. While we expect growth in Western Europe and North America to be relatively moderate, we are forecasting substantially stronger economic development in Eastern Europe, Latin America, and Asia.
The global cosmetics market will continue its long-term growth at 3 %. Despite some positive developments, we do not anticipate sustained improvement in the major markets of Western Europe. We expect the cosmetics market in Eastern Europe, Latin America, and Asia to perform well. tesa's markets are anticipated to pick up increasingly, particularly in the automotive segment.
The robust growth in Asia is expected to generate strong demand for raw materials and energy. We therefore expect no relief in prices for raw materials.
The Consumer business segment is planning higher sales growth in 2006 than in 2005 on a like-for-like basis, excluding currency translation effects. The EBIT margin (before special factors) is expected to increase further. tesa anticipates that sales growth will outperform the market and be up on the previous year. The EBIT margin will continue to improve.
For the Group as a whole, we anticipate sales growth to be stronger in 2006 than in 2005, and to exceed market growth. The EBIT margin (before special factors) is expected to increase further. This will also have a positive effect on our profi t after tax and return on sales after tax.
The realignment of the Consumer Supply Chain will result in aggregate additional costs of around €220 million (before tax) over the next three years. Approximately €70 million of this amount will be incurred in 2006 for the measures announced in February. The profi t after tax will decline by around €43 million in 2006 as a result.
Profi t after tax will include income of €361 million (after tax) from the sale of BSN medical.

The mood on international stock markets was marked by increasing optimism in the fi rst quarter of 2006. According to many observers, growth prospects in Europe and Japan have improved, so that a more uniform global economic growth is anticipated this year. Most indices are on a clear upswing and were hardly infl uenced by the latest interest rate increase by the European Central Bank. At the end of the quarter, the DAX was close to breaking through the 6,000-point barrier.
Indicators in the HPC (household and personal care) sector, which includes Beiersdorf, were clearly healthy in the fi rst three months of the year. The annual results for 2005, which were released during this period, contributed substantially to this performance.
The Beiersdorf share price was also boosted by the excellent fi nancial results of the previous year and the outlook for 2006. Above all, the new Consumer Business Strategy was a key factor in our share price performance. After its publication in November 2005, the fi nancial community showed growing interest in the four cornerstones of our "Passion for Success" strategy. After a rapid rise, our share price stabilized at a high level in the fi rst quarter, closing at €119.00 at the end of the quarter.

Beiersdorf share price performance in the first quarter
| Income Statement | |||
|---|---|---|---|
| (in € million) | Jan. 1 – Mar. 31, 2005 |
Jan. 1 – Mar. 31, 2006 |
Change in % |
| Sales | 1,173 | 1,275 | 8.7 |
| Cost of goods sold | -393 | -421 | 7.1 |
| Gross profi t | 780 | 854 | 9.5 |
| Marketing and selling expenses | -542 | -590 | 8.8 |
| Research and development expenses | -24 | -27 | 9.5 |
| General and administrative expenses | -56 | -61 | 9.3 |
| Other operating result | -13 | -14 | 11.6 |
| Operating result (EBIT) | 145 | 162 | 12.2 |
| Income from the sale of BSN medical | - | 371 | - |
| Other fi nancial result | 2 | - | - |
| Profi t before tax | 147 | 533 | 263.4 |
| Taxes on income | -55 | -71 | 29.5 |
| Profi t after tax | 92 | 462 | 402.1 |
| Minority interests | -2 | -1 | - |
| Net profi t | 90 | 461 | 409.2 |
| Earnings per share (in €)* | 1.20 | 6.09 | 409.2 |
*calculated on the basis of the weighted number of shares (2005/2006: 75,606,328)
| Balance Sheet | |||
|---|---|---|---|
| Assets (in € million) | Dec. 31, 2005 | Mar. 31, 2005 | Mar. 31, 2006 |
| Intangible assets | 34 | 50 | 32 |
| Property, plant, and equipment | 882 | 887 | 872 |
| Non-current fi nancial assets | 5 | 91 | 6 |
| Other non-current assets | 8 | - | 6 |
| Deferred tax assets | 33 | 27 | 31 |
| Non-current assets | 962 | 1,055 | 947 |
| Inventories | 536 | 590 | 585 |
| Trade receivables | 732 | 823 | 791 |
| Other current assets | 194 | 134 | 131 |
| Cash and cash equivalents | 483 | 255 | 980 |
| Current assets | 1,945 | 1,802 | 2,487 |
| 2,907 | 2,857 | 3,434 | |
| Equity and liabilities (in € million) | Dec. 31, 2005 | Mar. 31, 2005 | Mar. 31, 2006 |
| Shareholder's equity (Beiersdorf AG) excl. minority interests | 1,280 | 1,125 | 1,727 |
| Minority interests | 13 | 8 | 7 |
| Equity* | 1,293 | 1,133 | 1,734 |
| Non-current provisions | 430 | 490 | 427 |
| Non-current fi nancial liabilities | 29 | 17 | 26 |
| Other non-current liabilities | 8 | 2 | 7 |
| Deferred tax liabilities | 134 | 132 | 131 |
| Non-current liabilities | 601 | 641 | 591 |
| Current provisions | 407 | 435 | 516 |
| Trade payables | 369 | 316 | 369 |
| Current fi nancial liabilities | 74 | 141 | 60 |
| Other current liabilities | 163 | 191 | 164 |
| Current liabilities | 1,013 | 1,083 | 1,109 |
*before appropriation of net retained profi ts

| Cash Flow Statement | Jan. 1 – Mar. 31, | Jan. 1 – Mar. 31, |
|---|---|---|
| (in € million) | 2005 | 2006 |
| Cash and cash equivalents as of Jan. 1 | 290 | 483 |
| Operating result (EBIT) | 145 | 162 |
| Income taxes paid | -21 | -49 |
| Depreciation and amortization | 37 | 31 |
| Change in non-current provisions (excluding interest) | -3 | -4 |
| Gross cash fl ow | 158 | 140 |
| Change in inventories | -32 | -49 |
| Change in trade receivables and other assets | -168 | -72 |
| Change in liabilities and current provisions | 67 | 90 |
| Net cash fl ow from operating activities | 25 | 109 |
| Investments | -28 | -24 |
| Proceeds from divestments | 3 | 1 |
| Proceeds from the sale of BSN medical | - | 433 |
| Proceeds from interest, dividends, and other fi nancing activities | 13 | 8 |
| Net cash fl ow from investing activities | -12 | 418 |
| Free cash fl ow | 13 | 527 |
| Change in fi nancial liabilities | -46 | -17 |
| Interest and other fi nancing expenses paid | -9 | -11 |
| Net cash fl ow from fi nancing activities | -55 | -28 |
| Exchange rate fl uctuations and other effects on cash held | 7 | -2 |
| Net change in cash and cash equivalents | -35 | 497 |
| Cash and cash equivalents as of Mar. 31 | 255 | 980 |
| Statement of Changes in Equity | ||
|---|---|---|
| (in € million) | Jan 1. – Mar. 31, 2005 |
Jan. 1 – Mar. 31, 2006 |
| Beginning equity | 1,033 | 1,293 |
| Profi t after tax | 92 | 462 |
| Other changes | -8 | -12 |
| Currency translation adjustments | 16 | -9 |
| Ending equity | 1,133 | 1,734 |

| Annual General Meeting | May 17, 2006 |
|---|---|
| Dividend Payment | May 18, 2006 |
| Interim Report January to June 2006 | August 3, 2006 |
| Interim Report January to September 2006 Financial Analyst Meeting |
November 7, 2006 |
| Publication of Preliminary Group Results | January 2007 |
| Publication of Annual Report 2006 Annual Accounts Press Conference Financial Analyst Meeting |
February/March 2007 |
| Annual General Meeting | April 26, 2007 |
| Interim Report January to March 2007 | May 2007 |
| Interim Report January to June 2007 | August 2007 |
| Interim Report January to September 2007 Financial Analyst Meeting |
November 2007 |

Published by: Beiersdorf Aktiengesellschaft, Corporate Identity/Information, Unnastrasse 48, 20245 Hamburg, Germany Telephone: +49 40 4909-0, Telefax: +49 40 4909-3434 Additional Information: Press & PR: Telephone: +49 40 4909-2332, E-mail: [email protected] Investor Relations: Telephone: +49 40 4909-5000, E-mail: [email protected] Beiersdorf on the Internet: www.Beiersdorf.com


Printed copies may also be ordered from: Beiersdorf AG, Investor Relations, Unnastrasse 48, 20245 Hamburg, Germany Commercial Register Hamburg HRB 1787
A digital version of this Interim Report is available on the Internet at

Executive Board: Thomas-B. Quaas (Chairman), Peter Kleinschmidt, Pieter Nota, Markus Pinger, Rolf-Dieter Schwalb Supervisory Board Chairman: Dieter Ammer
www.Beiersdorf.com/interim_report.
W06/1771/83E
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.